Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants

This watch-and-measure (no experimental treatment required) study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).

Official registry: https://clinicaltrials.gov/study/NCT07532226 · Janssen-Cilag Ltd. · enrollment listed as 200

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 200 people at Lille. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients

Primary outcome (registry wording): Proportion of Participants Still Receiving Treatment at 1 Year

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
  • Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the watch-and-measure (no experimental treatment required) study
  • Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
  • Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements

Public study contact (from the registry)

Study Contact

844-434-4210

Participate-In-This-Study1@its.jnj.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBerlin, State of Berlin
Not a traditional drug phase: testing Glucocorticoid treatment for Osteoporosis

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.

NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit

RecruitingPhase 3Ciudad Autonoma de Buenos Aires, Buenos Aires
Phase 3: testing Deucravacitinib for Plaque Psoriasis

The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.

NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

FAQ about this NCT record

Is NCT07532226 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07532226?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07532226?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary